ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,737.10
-0.31%
S&P ASX All Technology
3,040.10
-0.87%
Brent Oil
77.795
-0.44%
US Dollar vs AUD
1.50489
0.67%
Bitcoin
70,464.25
2.41%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. AstraZeneca PLC (AZN)

  7. AstraZeneca PLC (AZN) News

AZN

AstraZeneca (AZN)

AstraZeneca PLC
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:AZN
DateTimeSourceHeadlineSymbolCompany
05/06/202400:02Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:AZNAstraZeneca PLC
04/06/202423:10IH Market NewsEconomic Worries May Lead To Weakness On Wall StreetNASDAQ:AZNAstraZeneca PLC
04/06/202421:00PR Newswire (US)AbelZeta announces clinical data showing preliminary anti-tumor activity for C-CAR031, an armored autologous GPC3 CAR-T, in patients with advanced hepatocellular carcinoma, at ASCO Annual Meeting 2024NASDAQ:AZNAstraZeneca PLC
04/06/202400:29Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
04/06/202400:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
03/06/202420:35Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
03/06/202404:32Business WireTAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trialNASDAQ:AZNAstraZeneca PLC
02/06/202422:05Business WireIMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placeboNASDAQ:AZNAstraZeneca PLC
02/06/202422:00Business WireENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapyNASDAQ:AZNAstraZeneca PLC
29/05/202406:30GlobeNewswire Inc.Cellectis Reports Financial Results for First Quarter 2024NASDAQ:AZNAstraZeneca PLC
28/05/202423:06Business Wireダトポタマブ デルクステカン、 進行性非扁平上皮非小細胞肺癌患者に対する第III相TROPION-Lung01試験において、 化学療法と比較して臨床的に有意な全生存期間の改善を示すNASDAQ:AZNAstraZeneca PLC
28/05/202420:15Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
28/05/202406:55Business WireDatopotamab-Deruxtecan zeigt in Phase-III-Studie TROPION-Lung01 klinisch signifikante Verbesserung des Gesamtüberlebens im Vergleich zur Chemotherapie bei Patienten mit fortgeschrittenem nicht squamösem, nicht kleinzelligem LungenkrebsNASDAQ:AZNAstraZeneca PLC
28/05/202403:14Business WireLe datopotamab deruxtecan a montré une survie globale cliniquement significative par rapport à la chimiothérapie chez des patients atteints d'un cancer avancé du poumon non à petites cellules et non squameuxNASDAQ:AZNAstraZeneca PLC
27/05/202421:00Business WireDatopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trialNASDAQ:AZNAstraZeneca PLC
24/05/202403:52Business WireAstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)NASDAQ:AZNAstraZeneca PLC
23/05/202421:00Business WireAstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)NASDAQ:AZNAstraZeneca PLC
22/05/202421:00Business WireAstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​NASDAQ:AZNAstraZeneca PLC
22/05/202408:44Business Wireアストラゼネカ、2030年までに総収益800億ドルを達成し、2030年以降も持続的な成長を実現するという野心的な目標を設定NASDAQ:AZNAstraZeneca PLC
22/05/202401:37Business WireAstraZeneca strebt für 2030 einen Gesamtumsatz von 80 Milliarden US-Dollar und ein nachhaltiges Wachstum nach 2030 anNASDAQ:AZNAstraZeneca PLC
22/05/202401:36Business WireAstraZeneca prévoit de réaliser un chiffre d’affaires total de 80 milliards de dollars d’ici 2030 et d’atteindre une croissance continue après 2030NASDAQ:AZNAstraZeneca PLC
21/05/202421:18IH Market NewsCalPERS to Oppose Exxon Mobil Directors; Microsoft Unveils Copilot+ PCs with AI Focus, and More NewsNASDAQ:AZNAstraZeneca PLC
21/05/202420:08Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
21/05/202416:00Business WireAstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030NASDAQ:AZNAstraZeneca PLC
20/05/202420:32Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AZNAstraZeneca PLC
20/05/202407:17Business WireNew data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary diseaseNASDAQ:AZNAstraZeneca PLC
13/05/202421:16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNASDAQ:AZNAstraZeneca PLC
06/05/202416:00GlobeNewswire Inc.Cellectis Announces Completion of the Additional Equity Investment by AstraZenecaNASDAQ:AZNAstraZeneca PLC
02/05/202421:00Business WireCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trialNASDAQ:AZNAstraZeneca PLC
01/05/202421:05Business WireAstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolioNASDAQ:AZNAstraZeneca PLC
 Showing the most relevant articles for your search:NASDAQ:AZN

Your Recent History

ASX
MQG
Macquarie
FX
AUDCAD
AUD vs CAD
ASX
WDC
Westfield
COIN
BTCUSD
Bitcoin
FX
AUDJPY
AUD vs Yen
NASDAQ
AMZN
Amazon.com
ASX
XJO
S&P ASX 200
NYSE
VZ
Verizon Communications
ASX
WOW
Woolworths
NASDAQ
NVDA
NVIDIA
ASX
NCM
Newcrest Mining
CCOM
SILVER
SILVER
ASX
TLS
Telstra
NYSE
JPM
JP Morgan Chase
NYSE
MRK
Merck
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved